|
Study | Number of patients | Complete remission (CR) [%] | Partial remission (PR) [%] | No change (NC), stable disease (SD) [%] | Overall response rate (CR + PR + SD) [%] | Reference |
|
Colorectal inoperable, liver metastasis | 60 | | | | | |
CDDP | 28 | 0 | 3.57 | 3.57 | 7.14 | [108] |
OXALI | 32 | 0 | 15.63 | 15.63 | 31.25 | |
Ovary (relapsed, advanced epithelial) | 26 | | | | | [87] |
Heavily pretreated | 13 | 0.00 | 23.08 | 38.46 | 61.54 | |
Not heavily pretreated | 13 | 30.77 | 23.08 | 38.46 | 92.31 | |
General oncology | 277 | | 21.50 | 37.00 | 58.50 | [109] |
TCM general oncology | 306 | | | | | |
Oncothermia + TCM | 75 | 6.67 | 57.33 | 26.67 | 90.67 | [110] |
Oncothermia + TCM + i.v.CTx | 65 | | | | | |
Passive arm | 51 | 7.84 | 60.78 | 15.69 | 84.31 | [110] |
Active arm | 14 | 14.29 | 64.28 | 21.43 | 100.00 | |
Oncothermia + TCM + abdominal perfusion | 87 | | | | 0.00 | |
Passive arm | 45 | 2.22 | 40 | 24.44 | 66.66 | [110] |
Active arm | 42 | 7.14 | 54.76 | 26.19 | 88.09 | |
Oncothermia + TCM + bladder perfusion | 37 | | | | | |
Passive arm | 24 | 0 | 50 | 12.5 | 62.50 | [110] |
Active arm | 13 | 7.69 | 53.85 | 30.77 | 92.31 | |
Oncothermia + TCM + RTx | 42 | | | | | |
Passive arm | 30 | 3.33 | 50 | 16.67 | 70.00 | [110] |
Active arm | 12 | 8.33 | 66.67 | 16.67 | 91.67 | |
Abdominal effusion + oncothermia | 49 | 4.08 | 53.06 | 16.38 | 73.52 | [110] |
Chronic pelvic inflammation | 283 | | | | | [111] |
Passive arm | 143 | | | | | |
Active arm | 140 | 46.10 | 29.40 | 19.60 | 95.10 | |
Chronic bronchitis, TCM + oncothermia | 35 | 30.00 | 24.30 | 25.70 | 80.00 | [111] |
Colon cancer study, phase II, prospective, three arms, randomized | 154 | | | | | [110] |
Clifford TCM | 53 | 5.7 | 28.3 | 18.9 | 52.90 | |
Monotherapy | 50 | 10 | 26 | 26 | 62.00 | |
Combined therapy | 51 | 13.7 | 45.1 | 23.5 | 82.30 | |
Colon operability | 7 | 71 | | | 71.00 | [112] |
Prostatitis | 72 | | | | | [111] |
Passive arm | 36 | 16.70 | 27.80 | 19.40 | 63.90 | |
Active arm | 36 | 41.70 | 36.10 | 22.20 | 100.00 | |
Prostate study | 184 | 49.5 | 15.2 | 15.8 | 80.50 | [113] |
Prostate cancer (Kleef) (Gleason Score 2–6) | 16 | | | | | [114] |
Oncothermia + hormone therapy | 8 | | | | 50 | |
Oncothermia monotherapy | 8 | | | | 37.5 | |
Prostate cancer (Kleef) (Gleason Score 7–9) | 17 | | | | | [114] |
Oncothermia + hormone therapy | 11 | | | | 81.82 | |
Oncothermia monotherapy | 6 | | | | 33.33 | |
Peyronie’s disease | 25 | | | | 100 | |
Pancreas | 42 | | 23.8 | 31 | 54.80 | [81] |
Pancreas | 30 | 3.3 | 33.3 | 40 | 76.60 | [79, 80] |
Esophagus | | 8 | 50 | 42 | 100.00 | [72] |
CRC liver | 22 | 5 | | 23 | 28 | [76] |
CRC liver | 15 | | 20 | 60 | 80.00 | [75] |
CRC liver oxalplatin | 12 | | | | 8.3 | [77] |
CRC liver cisplatin | 18 | | | | 27.8 | |
Advancer liver | 28 | | | | | [67] |
Oncothermia + RTx | 16 | | 31 | 50 | 81 | |
Oncothermia + CTx | 8 | | 13 | 25 | 38 | |
Oncothermia monotherapy | 4 | | | 25 | 25 | |
Brain | 19 | | 11 | 32 | 43 | [57] |
Asthma | 7 | | 75 | 10 | 85 | [115] |
Small-cell lung cancer (SCLC) | 38 | | 44.7 | 15.8 | 60.5 | [116] |
Benign tumors oncothermia + TCM | 35 | 54.3 | 25.7 | | 80.00 | [111] |
|